Navigation Links
Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
Date:12/10/2013

rease, and glutaminase inhibition.   Efficacious doses of CB-839 were well tolerated with no effects on hematologic cell counts or body weight.  The strong correlation between glutamine dependence and sensitivity to CB-839 in B cell tumor lines suggests that glutamine supports cell growth and survival in these tumors through metabolism of glutamine by glutaminase.  Calithera plans to advance CB-839 into Phase 1 clinical trials in patients with advanced solid and hematological tumors in early 2014.  

Calithera's in vitro and in vivo data on CB-839 were presented in a poster entitled, "Antitumor Activity of the Glutaminase Inhibitor CB-839 in Hematological Malignancies," (Abstract #4226), during the Chemical Biology and Experimental Therapeutics on December 9, 2013.

About Calithera Biosciences
Calithera is discovering and developing novel small molecule oncology therapeutics that inhibit pathways critical to tumor growth and survival.  The Calithera team has the experience and the ability needed to discover novel therapeutics and advance these discoveries through clinical development.  The company is applying this expertise to build a pipeline of anti-cancer compounds that are distinct from other oncology therapeutics.  Calithera's lead clinical candidate, CB-839, blocks glutaminase, an enzyme critical to tumor metabolism, and is poised to enter Phase 1 clinical testing.  Calithera Biosciences is a privately held company located in South San Francisco, CA.  For more information, please visit www.calithera.com.


'/>"/>
SOURCE Calithera Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
2. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
3. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
4. Proove Biosciences CEO Brian Meshkin Wins 2013 Bridging the Gap Award by the Greater Baltimore Committee
5. Sangamo BioSciences Announces Presentation At The 25th Annual Piper Jaffray Healthcare Conference
6. Telomere Biosciences Announces: TELO-100 with T-Activator 150, a Breakthrough in Telomere Science and Age Management
7. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
8. Proove Biosciences Will Be Exhibiting at the National Workers Compensation Conference and Expo on November 20-22
9. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
10. Sangamo BioSciences Announces Presentation Of Clinical Data From Alzheimers Disease Program
11. Ambit Biosciences Announces Third Quarter 2013 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Jose, California (PRWEB) September 19, 2014 ... Nanotechnology and its potential to revolutionize the world ... agencies, multinational corporations and small start-ups. The early ... funded research projects largely due to the high ... investments. Government budgets earmarked for this evolving technology ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. ... the development of high-value and difficult to manufacture proteins ... presenting at the 21 st Annual NewsMakers in ... . Bertrand Liang , chief executive officer ... development programs and business strategy on Friday, September 26, ...
(Date:9/19/2014)... 19, 2014 ... ) has announced the addition of the  "Micro ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... of the fastest-growing segments in the chromatography market. ... 2013, and expected to reach $2.0 billion by ...
(Date:9/18/2014)... September 18, 2014 HealthTronics, ... and interventional radiology products and services, announced that ... cryotherapy and cryoablation) versus external beam radiotherapy (EBRT) ... the American Urological Association (MAAUA) Annual Meeting in ... Relative Effectiveness of Cryosurgery and External Beam Radiation ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... ATLANTA, Oct. 12, 2011 CorMatrix Cardiovascular, Inc., ... delivering unique extracellular matrix (ECM) biomaterial devices that ... cardio-vascular tissue, announced today that the U.S. Food ... 510(k) clearance to market its CorMatrix® ECM® for ...
... 2011 Reportlinker.com announces that a new ... catalogue: Industrial Biotechnology ... http://www.reportlinker.com/p0655292/Industrial-Biotechnology-China-News-1109---Annual-Subscription.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Renewable_energy ... of Biotechnology Industry to be published in ...
... - Two pivotal trials initiated for treatment of iron ... - Shield Therapeutics (Shield), the independent specialty ... late-stage, mineral-derived hospital pharmaceuticals which address areas of high ... have been treated in the two Phase 3 clinical ...
Cached Biology Technology:CorMatrix Receives Carotid Artery Repair Indication for its CorMatrix® ECM® 2CorMatrix Receives Carotid Artery Repair Indication for its CorMatrix® ECM® 3Industrial Biotechnology China News 1109 - Annual Subscription 2Industrial Biotechnology China News 1109 - Annual Subscription 3Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 2Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10 3
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... the ideal animal in which to study the genes ... into tens of thousands of freshwater streams and lakes ... adapt to the new environment. , Breeding studies between ... up one of the genes that controls tooth number, ... regulation in a freshwater population is associated with a ...
(Date:9/17/2014)... accessible and affordable health care to reproductive technologies, ... on the ability of people to identify key ... and respectfully, and find the most defensible ways ... to support these societal conversations?, The Hastings Center ... Bioethical Issues have teamed up to publish a ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Why bioethics literacy matters 2Why bioethics literacy matters 3
... a huge portion of real estate in western North ... and fossils very different from those in adjacent terranes. ... tectonic styles, metamorphism, and volcanic origins, much like the ... new Geological Society of America Special Paper brings together ...
... Washington, DCMay 28, 2008The 2008 American Society for ... Diagnostic Immunology is presented to Steven A. Rosenberg, ... Surgery, Uniformed Services University of the Health Sciences, ... of Medicine and Health Sciences. Sponsored by Abbott ...
... for Microbiology (ASM) Merck Irving S. Sigal Memorial Award ... Genetics and Microbiology, University of Texas at Austin. Sponsored ... Memorial Award is presented in memory of Irving S. ... therapies to treat HIV/AIDS, to recognize excellence in basic ...
Cached Biology News:American Society for Microbiology honors Steven A. Rosenberg 2
... is a new-generation siRNA transfection reagent that ... 1 nM siRNA in a wide variety ... cell viability. Using low siRNA concentrations avoids ... when transfecting siRNA at higher concentrations, thereby ...
... Cell and Tissue Staining Kits are intended ... range of histological and cytological specimens. These ... antibodies manufactured by either R&D Systems or ... on the formation of the Avidin-Biotin Complex ...
... stranded RNA (dsRNA) has been shown to ... of organisms as well as insect cells ... inhibition of protein expression by utilizing sequence-specific, ... (mRNA). Attempts to induce RNA interference using ...
... jetSI-ENDO is an easy-to-use siRNA transfection reagent ... endogenous genes in a variety of cell ... with an optimized, straightforward protocol. High levels ... obtained following transfection of 20 to 100 ...
Biology Products: